Dialysis PatientsNCT07558239
Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors
An observational study of Dialysis Patients and Hypertension, run by Minia University.
Trial summary
Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients. Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Dialysis Patients, Hypertension, Atherosclerosis
- What is being tested?
- Ultrasound measurements of carotid intima- media thickness
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 24 Apr 2026to 1 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Renal dialysis patients
Who may be able to join
- 1. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.
Who cannot join
- o Active malignancy
- Acute infections
- Recent cardiovascular events (<3 months)
- Poor echocardiographic window for CIMT measurement
About this study
Official title: Association of Traditional Cardiovascular and Dialysis-Specific Risk Factors With Carotid Intima-Media Thickness in Hemodialysis Patients: A Cross-Sectional Study"
- Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.
- Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.
- Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.
Read the detailed description
- Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.
- Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.
- Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.
- Gap in knowledge: Few studies have comprehensively assessed the combined impact of these factors on CIMT in HD patients.
- Conditions
- Dialysis Patients, Hypertension, Atherosclerosis
- Being tested
- Ultrasound measurements of carotid intima- media thickness
- Keywords
- Renal dialysis, Carotid intima- media thickness
- Medical subject headings
- Hypertension, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound measurements of carotid intima- media thicknessOther
Ultrasound measurements of carotid intima- media thickness
What is being measured
The primary outcome is the main question the study is designed to answer.
• To determine the association between carotid intima - media thickness and: o Hypertension duration o HbA1c o LDL/HDL ratio o Dialysis duration o Parathyroid hormone (PTH) levels
Measured: 6 month
Secondary outcomes (1)
• To compare CIMT between: o Diabetics vs. non-diabetics o Short (<5 yrs) vs. long (≥5 yrs) dialysis duration o Patients with vs. without hyperparathyroidism (PTH >300 pg/m
Measured: 6month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2026
- Study start24 Apr 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Dialysis PatientsStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sohair Adeeb, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07558239
- Sponsor's protocol ID
- 1951/04/2026
- Status last verified
- Apr 2026
- First submitted
- 23 Apr 2026
- Last updated
- 30 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
https://doi.org/10.1016/j.atherosclerosis.2019.06.560
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Traditional Cardiovascular and Dialysis-Specific Risk Factors With Carotid Intima-Media Thickness in Hemodialysis Patients: A Cross-Sectional Study"
- ClinicalTrials.gov ID
- NCT07558239
- Acronym / sponsor ID
- 1951/04/2026
- Conditions
- Dialysis Patients, Hypertension, Atherosclerosis
- Keywords
- Renal dialysis, Carotid intima- media thickness
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 24 Apr 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Jul 2026 (estimated)
- First posted
- 30 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.
- Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.
- Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.
Detailed description
- Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.
- Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.
- Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.
- Gap in knowledge: Few studies have comprehensively assessed the combined impact of these factors on CIMT in HD patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Renal dialysis patients
Key inclusion criteria (1 listed)
- 1. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.
Key exclusion criteria (4 listed)
- o Active malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound measurements of carotid intima- media thicknessUltrasound measurements of carotid intima- media thickness | Other | – |
Primary outcome
• To determine the association between carotid intima - media thickness and: o Hypertension duration o HbA1c o LDL/HDL ratio o Dialysis duration o Parathyroid hormone (PTH) levels
Time frame: 6 month
1 secondary outcome
• To compare CIMT between: o Diabetics vs. non-diabetics o Short (<5 yrs) vs. long (≥5 yrs) dialysis duration o Patients with vs. without hyperparathyroidism (PTH >300 pg/m
Time frame: 6month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Backgroundhttps://doi.org/10.1016/j.atherosclerosis.2019.06.560
- Individual participant dataSharing planned: No
Related trials for Dialysis Patients
RecruitingPhase 3
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism, Chronic Kidney Disease
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Not yet recruitingObservational study
Malnutrition and Sarcopenia in Adults With Chronic Kidney Disease in Tunisia
Malnutrition, Sarcopenia
Not yet recruiting
Effects of Horticultural Therapy on Acute Stress and Salivary Cortisol Levels in Hemodialysis Patients
End-Stage Renal Disease, Renal Dialysis
RecruitingPhase 4
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Dialysis Patients and Hypertension, run by Minia University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
• To determine the association between carotid intima - media thickness and: o Hypertension duration o HbA1c o LDL/HDL ratio o Dialysis duration o Parathyroid hormone (PTH) levels (time frame: 6 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07558239, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.